Evidence map›Paper›PMID 30029166›Full record

ArticleDrug and alcohol dependence2018

Made from concentrate? A national web survey assessing dab use in the United States.

Kelly A Sagar, Ashley M Lambros, Mary Kathryn Dahlgren, Rosemary T Smith, Staci A Gruber

Abstract read
In one paragraph

Article in Drug and alcohol dependence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Gimmie the Gummies: Initial validation of the Edibles Marijuana Purchase Task.Experimental and clinical psychopharmacology · 2026
    Article
  3. Associations between Cannabis Consumption Methods and Cannabis Risk Perception.International journal of environmental research and public health · 2024
    Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kelly A SagarCognitive and Clinical Neuroimaging Core (CCNC), McLean Imaging Center, 115 Mill St, Belmont, MA, 02478, USA; Marijuana Investigations for Neuroscientific Discovery (MIND) Program, 115 Mill St, McLean Hospital, Belmont, MA, 02478, USA; Department of Psychiatry, Harvard Medical School, 401 Park Drive, Boston, MA, 02215 USA; Boston University School of Medicine, 72 E Concord St, Boston, MA, 02118, USA.
Ashley M LambrosCognitive and Clinical Neuroimaging Core (CCNC), McLean Imaging Center, 115 Mill St, Belmont, MA, 02478, USA; Marijuana Investigations for Neuroscientific Discovery (MIND) Program, 115 Mill St, McLean Hospital, Belmont, MA, 02478, USA.
Mary Kathryn DahlgrenCognitive and Clinical Neuroimaging Core (CCNC), McLean Imaging Center, 115 Mill St, Belmont, MA, 02478, USA; Marijuana Investigations for Neuroscientific Discovery (MIND) Program, 115 Mill St, McLean Hospital, Belmont, MA, 02478, USA.
Rosemary T SmithCognitive and Clinical Neuroimaging Core (CCNC), McLean Imaging Center, 115 Mill St, Belmont, MA, 02478, USA; Marijuana Investigations for Neuroscientific Discovery (MIND) Program, 115 Mill St, McLean Hospital, Belmont, MA, 02478, USA.
Staci A GruberCognitive and Clinical Neuroimaging Core (CCNC), McLean Imaging Center, 115 Mill St, Belmont, MA, 02478, USA; Marijuana Investigations for Neuroscientific Discovery (MIND) Program, 115 Mill St, McLean Hospital, Belmont, MA, 02478, USA; Department of Psychiatry, Harvard Medical School, 401 Park Drive, Boston, MA, 02215 USA. Electronic address: gruber@mclean.harvard.edu.

Funding

Marijuana: Neurobiologic Correlates of Age of OnsetR01DA032646 · NIDA · MCLEAN HOSPITAL · PI GRUBER, STACI A · 2012 to 2016
$2.0M
NIDA NIH HHS R01 DA032646
6 · The paper itself

Abstract

backgroundCannabis concentrates, including dabs, contain extremely high levels of Δ

methods4077 respondents completed a survey designed to assess the use of conventional flower cannabis relative to dabs. Individuals provided information about frequency and magnitude of use, and also completed the Marijuana Motives Measure and Severity of Dependence Scale to examine whether dab users have different motives for use and/or demonstrate more severe consequences of use compared to those who only use conventional flower products.

results58% of respondents reported they had tried dabs at least once and 36.5% endorsed regular use (once a month or more). Those who use regularly use dabs were significantly more likely to report using for experimentation (feeling "curious") relative to reasons for using conventional flower products. Interestingly, motives reflecting positive effects (i.e., coping, sleep problems, relieving social anxiety) were endorsed more highly for flower use. In addition, regular dab users reported being more worried about their use of cannabis products relative to those who had tried dabs but did not use regularly.

conclusionsResults indicate that cannabis consumers do not necessarily choose dabs over flower products for positive effects, but rather appear to choose these highly potent products for experimentation. As concentrate use may lead to increased cannabis-related problems, studies directly assessing concentrate users are needed.

Indexed as

CannabisSurveys and QuestionnairesAdultAnxietyDiazonium CompoundsDronabinolFemaleHumansMaleMarijuana AbuseMiddle AgedSulfanilic AcidsUnited Statesdiazobenzenesulfonic acidDiazonium CompoundsDronabinolSulfanilic AcidsCannabisConcentratesDabsMarijuanaPotencySurveyTHC

Identifiers

PMID30029166
PMCPMC9036911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.